Small Caps

When the cash isn’t where the accounts say it is: the Patisserie Valerie story

The Patisserie Valerie story shows why small-cap investors must test cash, milestones and dilution risk before trusting the narrative or the price action.

By Cameron Oliver · June 18, 2026

Small-cap investing is where weak research gets punished fastest. The Little Book of Small-Caps is clear on one point: before you get excited about a story, you need a repeatable way to separate progress from performance theatre.

Reviewed by Sarah Okafor, Editor · June 18, 2026, 11:42 pm bst

In this article

The Short Version

Judge small-cap progress by evidence, not by the pace of announcements.
Ask whether each milestone changes the business, the cash runway or the risk profile.
Separate measurable proof from management optimism and market momentum.
This is educational research structure, not a recommendation to buy or sell any share.

Why Evidence Matters More Than Momentum

The Patisserie Valerie story matters because smaller companies can move a long way on attention before the underlying business has changed very much. Momentum can be useful information, but it is not proof. The safer habit is to ask what the latest update proves that was not already true yesterday.

The book’s discipline is simple: keep returning to the evidence. Small-cap investors are often shown possibility, ambition and timelines. The job is to work out which parts are measurable and which parts are still promises.

The Core Test

The core test is cash runway and dilution risk. A useful announcement should help you answer at least one practical question: how many months of cash the company has at its current burn rate, whether the next milestone arrives before the next funding need, or whether new money improves the business or merely keeps it alive.

The common failure mode is treating survival funding as if it were growth capital. That is why a rising share price or a busy news page should never replace the slower work of reading the announcement, checking the numbers and asking what has materially changed.

Milestones Need A Baseline

A milestone only means something if you know the baseline. Was it promised in an earlier update? Was it needed to keep the plan on track? Does it affect revenue, regulation, funding, production, customer adoption or the balance sheet?

Without that baseline, progress becomes a feeling. With it, you can tell whether the company has reduced uncertainty or merely repeated the same ambition in fresher language.

This is especially important in sectors where the journey is naturally long. A technology company may need product adoption, a biotech company may need data, and a resources company may need permits, funding and technical work. The label changes, but the discipline is the same. A milestone should narrow the range of uncertainty. If it does not, it may be a useful update, but it is not yet strong evidence.

Cash Still Sets The Clock

Even genuine progress has to be matched against cash. A small-cap can hit technical milestones and still dilute shareholders if the next stage needs more funding than the current balance sheet can support.

That does not make every raise bad. It means funding is part of the evidence. Ask whether new capital would push the company through a value-creating stage or simply buy more time for the same unresolved story.

The useful question is not simply whether the company can raise money. In buoyant markets, many companies can. The better question is what existing shareholders receive in exchange for that dilution. If the money funds a clearly defined next proof point, the trade-off may be understandable. If it funds more announcements while the hard evidence remains distant, the cost is easier to miss.

A Worked Example

A company has a promising asset and twelve months of cash. If the next meaningful proof point is eighteen months away, the investment case includes a funding event whether or not management says so plainly.

The plain version is this: mark the claim, mark the evidence, then mark the next dependency. If those three things do not line up, momentum is doing more work than progress.

Now compare two fictional announcements. One says the company has signed a memorandum of understanding with a possible customer. That may be interesting, but it is usually early. The other says the company has received a first commercial order, with a named delivery window and payment terms. Both can move sentiment, but only one gives you firmer evidence that interest has turned into demand.

Even then, the work is not finished. You would still ask whether the order is material, whether it repeats, whether margins are attractive and whether the company can deliver without stretching the balance sheet. Small-cap evidence usually arrives in layers. The first layer may justify attention. Later layers have to justify conviction.

The Cross-Sector Questions That Still Matter

No matter the sector, a small-cap evidence checklist should answer four things: what has been proven, what is still uncertain, how the company funds the next stage, and what would make you change your mind. The book’s edge is that it pushes you back to process when the narrative is loud.

That last question matters more than investors like to admit. Before you get attached to a story, write down what would disprove it. A missed deadline might be noise. A repeated pattern of missed deadlines may be evidence. A small contract might be a first step. A series of tiny contracts presented as transformational may tell you something else.

The same discipline helps with company cash claims. If management says liquidity is comfortable, go back to the last filed accounts and recent financing announcements. The point is not to assume fraud. It is to make sure the reassurance on the page matches the evidence in the numbers.

What This Means For You

If you plan to invest in a small-cap, write the evidence test before you read the latest announcement. That simple habit changes the order of your thinking. You are no longer asking whether the update sounds good. You are asking whether it proves enough.

The practical benefit is focus: fewer stories, more evidence, and a clearer view of dilution, delays and downside risk.

It also gives you a calmer relationship with price moves. A rising share price can be a sign that other investors are waking up to the same evidence. It can also be a sign that expectation is getting ahead of reality. When you have written down the evidence in advance, you are less likely to let the chart rewrite your thesis for you.

None of this removes risk. Small-caps remain volatile, illiquid and vulnerable to disappointment. The point is to make the risk more explicit. Momentum can invite you to act quickly. Evidence gives you permission to slow down.

In Plain English

Momentum tells you that people are paying attention. Evidence tells you whether the company is actually getting stronger. In small-caps, you need both on the page, but only one should drive your judgement.